BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 25515960)

  • 1. The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia.
    Schinnerl D; Fortschegger K; Kauer M; Marchante JR; Kofler R; Den Boer ML; Strehl S
    Blood; 2015 Feb; 125(8):1282-91. PubMed ID: 25515960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice.
    Jamrog L; Chemin G; Fregona V; Coster L; Pasquet M; Oudinet C; Rouquié N; Prade N; Lagarde S; Cresson C; Hébrard S; Nguyen Huu NS; Bousquet M; Quelen C; Brousset P; Mancini SJC; Delabesse E; Khamlichi AA; Gerby B; Broccardo C
    Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10357-10362. PubMed ID: 30257940
    [No Abstract]   [Full Text] [Related]  

  • 3. PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells.
    Fazio G; Palmi C; Rolink A; Biondi A; Cazzaniga G
    Cancer Res; 2008 Jan; 68(1):181-9. PubMed ID: 18172310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EBF1-JAK2 inhibits the PAX5 function through physical interaction with PAX5 and kinase activity.
    Kojima Y; Kawashima F; Yasuda T; Odaira K; Inagaki Y; Yamada C; Muraki A; Noura M; Okamoto S; Tamura S; Iwamoto E; Sanada M; Matsumura I; Miyazaki Y; Kojima T; Kiyoi H; Tsuzuki S; Hayakawa F
    Int J Hematol; 2023 Jul; 118(1):65-74. PubMed ID: 37149540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ph-like acute lymphoblastic leukemia with a novel PAX5-KIDINS220 fusion transcript.
    Sakamoto K; Imamura T; Kanayama T; Yano M; Asai D; Deguchi T; Hashii Y; Tanizawa A; Ohshima Y; Kiyokawa N; Horibe K; Sato A
    Genes Chromosomes Cancer; 2017 Apr; 56(4):278-284. PubMed ID: 27870151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PAX5-JAK2 translocation acts as dual-hit mutation that promotes aggressive B-cell leukemia via nuclear STAT5 activation.
    Jurado S; Fedl AS; Jaritz M; Kostanova-Poliakova D; Malin SG; Mullighan CG; Strehl S; Fischer M; Busslinger M
    EMBO J; 2022 Apr; 41(7):e108397. PubMed ID: 35156727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia.
    Nebral K; Denk D; Attarbaschi A; König M; Mann G; Haas OA; Strehl S
    Leukemia; 2009 Jan; 23(1):134-43. PubMed ID: 19020546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of RUNX1-JAK2 in Human Induced Pluripotent Stem Cell-Derived Hematopoietic Cells Activates the JAK-STAT and MYC Pathways.
    Fortschegger K; Husa AM; Schinnerl D; Nebral K; Strehl S
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The reduced and altered activities of PAX5 are linked to the protein-protein interaction motif (coiled-coil domain) of the PAX5-PML fusion protein in t(9;15)-associated acute lymphocytic leukemia.
    Qiu JJ; Chu H; Lu X; Jiang X; Dong S
    Oncogene; 2011 Feb; 30(8):967-77. PubMed ID: 20972455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional heterogeneity of PAX5 chimeras reveals insight for leukemia development.
    Fortschegger K; Anderl S; Denk D; Strehl S
    Mol Cancer Res; 2014 Apr; 12(4):595-606. PubMed ID: 24435167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional analysis of a novel fusion protein PAX5-KIDINS220 identified in a pediatric Ph-like ALL patient.
    Kanayama T; Imamura T; Mayumi A; Soma E; Sakamoto K; Hayakawa F; Tanizawa A; Kiyokawa N; Hosoi H
    Int J Hematol; 2020 Nov; 112(5):714-719. PubMed ID: 32656633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B Cell Linker Protein (BLNK) Is a Selective Target of Repression by PAX5-PML Protein in the Differentiation Block That Leads to the Development of Acute Lymphoblastic Leukemia.
    Imoto N; Hayakawa F; Kurahashi S; Morishita T; Kojima Y; Yasuda T; Sugimoto K; Tsuzuki S; Naoe T; Kiyoi H
    J Biol Chem; 2016 Feb; 291(9):4723-31. PubMed ID: 26703467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PAX5 is part of a functional transcription factor network targeted in lymphoid leukemia.
    Okuyama K; Strid T; Kuruvilla J; Somasundaram R; Cristobal S; Smith E; Prasad M; Fioretos T; Lilljebjörn H; Soneji S; Lang S; Ungerbäck J; Sigvardsson M
    PLoS Genet; 2019 Aug; 15(8):e1008280. PubMed ID: 31381561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase.
    Cuesta-Domínguez Á; Ortega M; Ormazábal C; Santos-Roncero M; Galán-Díez M; Steegmann JL; Figuera Á; Arranz E; Vizmanos JL; Bueren JA; Río P; Fernández-Ruiz E
    PLoS One; 2012; 7(2):e32451. PubMed ID: 22384256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromosomal translocation-mediated evasion from miRNA induces strong MEF2D fusion protein expression, causing inhibition of PAX5 transcriptional activity.
    Hirano D; Hayakawa F; Yasuda T; Tange N; Yamamoto H; Kojima Y; Morishita T; Imoto N; Tsuzuki S; Mano H; Naoe T; Kiyoi H
    Oncogene; 2019 Mar; 38(13):2263-2274. PubMed ID: 30478446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative genomics reveals multistep pathogenesis of E2A-PBX1 acute lymphoblastic leukemia.
    Duque-Afonso J; Feng J; Scherer F; Lin CH; Wong SH; Wang Z; Iwasaki M; Cleary ML
    J Clin Invest; 2015 Sep; 125(9):3667-80. PubMed ID: 26301816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of PML as novel PAX5 fusion partner in childhood acute lymphoblastic leukaemia.
    Nebral K; König M; Harder L; Siebert R; Haas OA; Strehl S
    Br J Haematol; 2007 Oct; 139(2):269-74. PubMed ID: 17897302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dominant-negative mechanism of leukemogenic PAX5 fusions.
    Kawamata N; Pennella MA; Woo JL; Berk AJ; Koeffler HP
    Oncogene; 2012 Feb; 31(8):966-77. PubMed ID: 21765475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EBF1 and Pax5 safeguard leukemic transformation by limiting IL-7 signaling, Myc expression, and folate metabolism.
    Ramamoorthy S; Kometani K; Herman JS; Bayer M; Boller S; Edwards-Hicks J; Ramachandran H; Li R; Klein-Geltink R; Pearce EL; Grün D; Grosschedl R
    Genes Dev; 2020 Nov; 34(21-22):1503-1519. PubMed ID: 33004416
    [No Abstract]   [Full Text] [Related]  

  • 20. Activating PAX gene family paralogs to complement PAX5 leukemia driver mutations.
    Hart MR; Anderson DJ; Porter CC; Neff T; Levin M; Horwitz MS
    PLoS Genet; 2018 Sep; 14(9):e1007642. PubMed ID: 30216339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.